サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1701263

結核診断の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Type (Detection Of Latent Infection, Phage Assay, Nucleic Acid Testing), By End-use (Diagnostic Laboratories, Hospitals & Clinic), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
結核診断の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年03月11日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

結核診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の結核診断市場規模は2025年から2030年にかけてCAGR 5.8％を記録し、2030年までに31億8,000万米ドルに達すると予測されています。

インターフェロンγリリースアッセイ（IGRA）、血清学的手法、核酸検査などの高度な診断法の登場が、診断薬の高い使用率につながっています。さらに、抗原アッセイなどのPOC（Point of Care）技術も結核の診断率を高めています。

POC診断を含むこれらの高度な方法は、手頃な価格で正確かつ簡便であり、迅速な結果が得られます。さらに、結核の負担増が市場成長の主な要因となっています。世界保健機関（WHO）によると、2014年の結核患者の世界推計は約960万人でした。この高い有病率により、政府、ヘルスケア機関、調査機関、市場関係者は、この感染症の発生を抑制するための努力を開始しました。

高負担地域における検診率の上昇、手頃な価格の診断薬、高度な調査手法、迅速な臨床判断、死亡率の低下が開発の焦点となっています。予防的・治療的診断率の向上は、こうした取り組みの最終的な成果です。このため、診断検査に対する需要が急増し、結核診断市場が拡大しています。

結核診断市場レポートハイライト

  • 潜伏感染検出分野（皮膚テスト＆IGRA）は、結核の有病率増加に牽引され、2024年に40.59%のシェアで市場をリード。
  • 薬剤耐性（DST）は予測期間中に最も速いCAGRを達成すると予測されます。DSTは、様々な抗生物質に対する結核菌の感受性を評価し、どの薬剤が治療に有効かを特定します。
  • 2024年には、診断ラボ部門が結核診断市場で最大の売上シェアを占め、その原動力となりました。
  • 病院・クリニック分野は、ヘルスケア環境における結核検査率の上昇に牽引され、大きく成長する見込みです。
  • アジア太平洋の結核診断市場は、2024年の収益シェア37.18％で市場を独占し、予測期間中に最も速い成長が見込まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 結核診断市場の変数、動向、範囲

  • 市場力学
    • 市場ドライバー分析
    • 市場抑制要因分析
    • 市場機会分析
  • 結核診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析
    • ケーススタディ

第4章 結核診断市場：タイプ別推定・動向分析

  • タイプ別市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 世界の結核診断市場：タイプ別展望
  • 潜在感染の検出（皮膚テストとIGRA）
  • ファージアッセイ
  • 薬剤耐性検出（DST）
  • 核酸検査
  • 放射線学的方法
  • サイトカイン検出アッセイ
  • その他

第5章 結核診断市場：最終用途別推定・動向分析

  • 最終用途市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 世界の結核診断市場：最終用途別展望
  • 診断検査室
  • 病院と診療所
  • その他

第6章 結核診断市場：地域別推定・動向分析、製品別、タイプ別、最終用途別

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 世界地域市場のスナップショット
  • 市場規模と予測動向分析、2018年から2030年まで：
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • 主要企業の市場シェア/ポジション分析、2024年
  • 企業プロファイル
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 4 North America Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 8 Canada Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 12 Europe Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 13 UK Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 14 UK Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 16 Germany Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 17 France Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 18 France Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 20 Italy Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 22 Spain Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 Denmark Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 24 Denmark Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 25 Sweden Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 26 Sweden Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 28 Norway Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 32 Japan Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 33 China Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 34 China Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 India Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 36 India Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 38 Australia Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 46 Brazil Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 50 MEA Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 52 South Africa Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 56 UAE Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Tuberculosis Diagnostics market estimates and forecasts by type, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Tuberculosis Diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Tuberculosis Diagnostics market outlook
  • Fig. 9 Tuberculosis Diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Tuberculosis Diagnostics market driver impact
  • Fig. 15 Tuberculosis Diagnostics market restraint impact
  • Fig. 16 Tuberculosis Diagnostics market strategic initiatives analysis
  • Fig. 17 Tuberculosis Diagnostics market: Type analysis
  • Fig. 18 Tuberculosis Diagnostics market: Type outlook and key takeaways
  • Fig. 19 Detection of Latent Infection (Skin Test & IGRA) market estimates and forecast, 2018 - 2030
  • Fig. 20 Phage assay market estimates and forecast, 2018 - 2030
  • Fig. 21 Detection of Drug Resistance (DST) market estimates and forecast, 2018 - 2030
  • Fig. 22 Nucleic Acid Testing market estimates and forecast, 2018 - 2030
  • Fig. 23 Radiographic method market estimates and forecast, 2018 - 2030
  • Fig. 24 Cytokine detection assay market estimates and forecast, 2018 - 2030
  • Fig. 25 Others market estimates and forecast, 2018 - 2030
  • Fig. 26 Lumbar puncture market estimates and forecast, 2018 - 2030
  • Fig. 27 Nerve conduction studies market estimates and forecast, 2018 - 2030
  • Fig. 28 Electromyography market estimates and forecast, 2018 - 2030
  • Fig. 29 Others market estimates and forecast, 2018 - 2030
  • Fig. 30 Tuberculosis Diagnostics market: End use movement analysis
  • Fig. 31 Tuberculosis Diagnostics market: End use outlook and key takeaways
  • Fig. 32 Diagnostic laboratories market estimates and forecast, 2018 - 2030
  • Fig. 33 Hospitals & clinics market estimates and forecast, 2018 - 2030
  • Fig. 34 Others market estimates and forecast, 2018 - 2030
  • Fig. 35 Global Tuberculosis Diagnostics market: Regional movement analysis
  • Fig. 36 Global Tuberculosis Diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global Tuberculosis Diagnostics market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America: SWOT
  • Fig. 44 Europe SWOT
  • Fig. 45 Asia Pacific SWOT
  • Fig. 46 Latin America SWOT
  • Fig. 47 MEA SWOT
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 55 France market estimates and forecasts, 2018 - 2030
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 62 China market estimates and forecasts, 2018 - 2030
  • Fig. 63 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 64 India market estimates and forecasts, 2018 - 2030
  • Fig. 65 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 66 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 67 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 68 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 69 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Market share of key market players- Tuberculosis Diagnostics market
  • Fig. 77 Key Company Categorization
  • Fig. 78 Company Market Share/Position Analysis, 2024
  • Fig. 79 Strategic Framework
目次
Product Code: GVR-1-68038-098-9

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.18 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • The latent infection detection segment (Skin Test & IGRA) led the market in 2024 with a 40.59% share, driven by the increasing prevalence of tuberculosis.
  • Drug Resistance (DST) is projected to achieve the fastest CAGR during the forecast period. DST evaluates the susceptibility of Mycobacterium tuberculosis to various antibiotics, identifying which drugs are effective for treatment.
  • In 2024, the diagnostic laboratories segment dominated the TB diagnostics market with the largest revenue share, driven by initiatives to enhance patient outcomes through accessible, retail-level diagnostic services.
  • The hospitals and clinics segment is poised for significant growth, driven by increasing TB testing rates in healthcare settings.
  • The tuberculosis diagnostics market in Asia Pacific dominated the market with revenue share of 37.18% in 2024 and is expected to witness the fastest growth over the forecast period.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Tuberculosis Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Tuberculosis Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Tuberculosis Diagnostics Market by Type Outlook
  • 4.4. Detection of Latent Infection (Skin Test & IGRA)
    • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.5. Phage Assay
    • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.6. Detection of Drug Resistance (DST)
    • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.7. Nucleic Acid Testing
    • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.8. Radiographic Method
    • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.9. Cytokine Detection Assay
    • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Tuberculosis Diagnostics Market by End Use Outlook
  • 5.4. Diagnostic Laboratories
    • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.5. Hospitals & Clinics
    • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Abbott
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology Type benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. QIAGEN
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology Type benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Thermo Fisher Scientific Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology Type benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. BD
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology Type benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. F. Hoffmann-La Roche AG
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology Type benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Hologic, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology Type benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Cepheid
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology Type benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. DiaSorin S.p.A.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology Type benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Hain Lifescience GmbH
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology Type benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Oxford Immunotec
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology Type benchmarking
      • 7.4.10.4. Strategic initiatives